Stay updated with breaking news from மைக்கேல் ஐசோன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celltrion s COVID treatment has efficacy in Phase 2 trials Posted : 2021-01-13 21:08 By Nam Hyun-woo Celltrion said Wednesday that its Regkirona anti-COVID-19 drug, also known as CT-P59, has had its efficacy proven for the treatment of patients with mild to moderate symptoms of the coronavirus disease in global Phase 2 clinical trials. This bodes well for the company to win domestic approval for use of the treatment in Korea. The biotech company filed for conditional approval for use with the Ministry of Food and Drug Safety, Dec. 29. Given the ministry has shortened its review process to a maximum 40 days and the trials have shown a favorable outcome, the treatment is expected to be marketed here as early as late this month. ....
Ison warned that if significant mitigation measures aren’t put in place nationally, the number of cases and deaths will continue to rise. “The message is for people to keep focused on what is individually within their control and work on countering some of that sadness and loneliness,” said Abigail Turner, associate professor of epidemiology and internal medicine at Ohio State University Wexner Medical Center in Columbus. “Find safe ways to be with people. Pull out your blankets and your warmest coats and sit in the winter sunshine … Call and play games over the internet … The end is in sight, but it’s not here.” ....
What will 2021 look like? 7 infectious disease experts discuss today.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from today.com Daily Mail and Mail on Sunday newspapers.
Daily life in the south and southwest suburbs was changed dramatically by the COVID-19 pandemic in 2020, with the arrival of a vaccine late in the year bringing hope of turning the corner ....
Overstock of monoclonal antibodies sits unused in hospitals: Report Print this article Monoclonal antibodies to treat COVID-19 have been met with a hesitant response by hospitals, prompting piles of the drug to sit unused as coronavirus cases surge. Therapies from Eli Lilly and Regeneron, which were approved for emergency use in November, are now seeing a lack of interest and awareness by primary-care doctors despite previous concerns that the drug would be in short supply, according to a report by the Physicians are not ordering the drug, said Michael Ison, an infectious disease physician at Northwestern Memorial Hospital who is helping lead the monoclonal antibody rollout across northern Illinois. ....